<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731469</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-131-1</org_study_id>
    <nct_id>NCT02731469</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Tolerance, Safety and Immunogenicity of Single Injection of Increasing Doses of BCD-131 to Healthy Volunteers Compared to Mircera® and Aranesp®</brief_title>
  <official_title>Open Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Tolerance, Safety and Immunogenicity of Single Injection of Increasing Doses of BCD-131 to Healthy Volunteers Compared to Mircera® (F. Hoffman-La Roche Ltd., Switzerland) and Aranesp® (Amgen Europe B.V., Netherlands)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-131 is pegylated darbepoetin beta. BCD-131-1 is open clinical trial to evaluate
      pharmacokinetics, pharmacodynamics, tolerance, safety and immunogenicity of single injection
      of increasing doses of BCD-131 to healthy volunteers compared to Mircera® and Aranesp®.
      Clinical trial will be conducted in two stages. On first stage the optimal dose for
      therapeutic use of BCD-131 will be determined (subcutaneous injections). On second stage the
      determined dose will be injected subcutaneously and intravenously.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (0-1176 hours) and AUC (0-∞)</measure>
    <time_frame>0 to 1176 hours post-dose</time_frame>
    <description>Area under curve (AUC) &quot;concentration - time&quot; from 0 hours to 1176 hours and to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 to 1176 hours post-dose</time_frame>
    <description>Maximal concentration of drug in blood after single injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0 to 1176 hours post-dose</time_frame>
    <description>Time from 9 hours to time of maximal concentration of drug in blood after single injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>0 to 1176 hours post-dose</time_frame>
    <description>Half-life of drug in blood after single injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>0 to 1176 hours post-dose</time_frame>
    <description>Elimination rate constant of drug in blood after single injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of BCD-131</measure>
    <time_frame>0 to 1176 hours post-dose</time_frame>
    <description>Clearance of BCD-131 in blood after single injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC (0-1176 hours) - reticulocytes</measure>
    <time_frame>0 to 1176 hours</time_frame>
    <description>Area under effect curve (AUEC) &quot;absolute reticulocyte count - time&quot; from 0 to 1176 hours post-dose after single injection of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC (0-1176 hours) - hemoglobin</measure>
    <time_frame>0 to 1176 hours</time_frame>
    <description>Area under effect curve (AUEC) &quot;hemoglobin - time&quot; from 0 to 1176 hours post-dose after single injection of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AC-Emax - reticulocytes</measure>
    <time_frame>0 to 1176 hours</time_frame>
    <description>Absolute maximum of reticulocyte count (AC-Emax - reticulocytes) after single injection of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AC-Emax - hemoglobin</measure>
    <time_frame>0 to 1176 hours</time_frame>
    <description>Absolute maximum of hemoglobin (AC-Emax - hemoglobin) after single injection of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of pain after subcutaneous injection according to visual analog scale</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events (AE)/ serious adverse events (SAE)</measure>
    <time_frame>0 to 1176 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of local reactions</measure>
    <time_frame>0 to 1176 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE/SAE 3-4 grade CTCAE</measure>
    <time_frame>0 to 1176 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of early withdrawal due to AE</measure>
    <time_frame>0 to 1176 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with binding antibodies to BCD-131</measure>
    <time_frame>1176 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Reticulocyte Count</condition>
  <arm_group>
    <arm_group_label>BCD-131, 0.05 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 0.15 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 0.40 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 1.05 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 1.70 mcg/kg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 2.25 mcg/kg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 4.45 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mircera®, 1.20 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aranesp®, 0.45 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, optimal dose, intravenously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, optimal dose, subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-131</intervention_name>
    <arm_group_label>BCD-131, 0.05 mcg/kg subcutaneously</arm_group_label>
    <arm_group_label>BCD-131, 0.15 mcg/kg subcutaneously</arm_group_label>
    <arm_group_label>BCD-131, 0.40 mcg/kg subcutaneously</arm_group_label>
    <arm_group_label>BCD-131, 1.05 mcg/kg subcutaneously</arm_group_label>
    <arm_group_label>BCD-131, 1.70 mcg/kg SC</arm_group_label>
    <arm_group_label>BCD-131, 2.25 mcg/kg SC</arm_group_label>
    <arm_group_label>BCD-131, 4.45 mcg/kg subcutaneously</arm_group_label>
    <arm_group_label>BCD-131, optimal dose, intravenously</arm_group_label>
    <arm_group_label>BCD-131, optimal dose, subcutaneously</arm_group_label>
    <other_name>pegylated darbepoetin beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mircera®</intervention_name>
    <arm_group_label>Mircera®, 1.20 mcg/kg subcutaneously</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aranesp®</intervention_name>
    <arm_group_label>Aranesp®, 0.45 mcg/kg subcutaneously</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Volunteer are healthy according to screening investigation, including absence of history of
        hematologic diseases. Results of hematological, biochemical blood analyses are in normal
        ranges, including serum ferritin, endogenous erythropoietin No history of alcohol or drug
        abuse.

        Exclusion Criteria:

        History of using any erythropoiesis stimulating agents. Acute hemorrhage, donation of blood
        / plasma or blood transfusions during the 2 months prior to study enrollment.

        History of chronic hemorrhage. History of allergy to any of the excipients of study drug.
        Current use of drugs or history of diseases that could influence study drug
        pharmacokinetics.

        Full list of inclusion and exclusion criteria can be found in Protocol of the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>JCS BIOCAD</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <last_update_submitted>May 3, 2016</last_update_submitted>
  <last_update_submitted_qc>May 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

